Back to Quality Research
COLLCollegium Pharmaceutical Inc
Health Care · Biotechnology: Pharmaceutical Preparations · Small
$22.96−2.30%
As of 23 Oct 2026Mkt cap $753M
Stage 13
AVOID
Fundamentals
57.6/75
Technical
4.2/15
Independent
61.8/90
GCAE viewstructural technical damage is a hard non-actionable condition
Price
- 1M
- +1.4%
- 3M
- −35.4%
- 6M
- −29.4%
- 1Y
- −35.7%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 18.5xHist median 20.8x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 2.8x
- FCF yield
- 36.0%
Quality
- ROIC
- 17.1%
- Operating margin
- 26.9%
- FCF margin
- 42.0%
- Current ratio
- 1.6x
Growth
- Revenue growth
- +23.6%Latest FY YoY
- Revenue CAGR
- +29.6%
- EPS CAGR
- −1.8%
- FCF CAGR
- +34.0%
Capital
- Share-count trend
- −2.5%3Y annualised
- Net debt
- $345M1.0x OCF
Annual trend
- CAGR 2021–2025
- +29.6%
- Latest · 2025
- $1B
- YoY
- +23.6%
GCAE Research
- Quality Research
- PRE-AI
- Acceleration Radar
- FUNDAMENTAL DECELERATION
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- UNRESEARCHED · NEW RESEARCH
Key takeaway
Awaiting four-lens research.
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-05
- New current Route A/Route B candidate has no completed four-lens research.
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- damaged
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded